Slowly progressive insulin-dependent (type 1) diabetes positive for anti-GAD antibody ELISA test may be strongly associated with a future insulin-dependent state
Authors:
- 1 January 2017
- journal article
- research article
- Published by Japan Endocrine Society in Endocrine Journal
- Vol. 64 (2) , 163-170
Abstract
Slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM), believed to be caused by β-cell destruction through islet-cell autoimmunity, gradually progresses to an insulin-dependent state over time. Although the presence of anti-glutamic acid decarboxylase antibody (GADA) is required for the diagnosis of SPIDDM, a recent change in the GADA assay kit from radioimmunoassay (RIA) to enzyme-linked immunosorbent assay (ELISA) yields mismatched GADA test results between the two kits, leading to confusion in understanding the pathological conditions of SPIDDM in Japan. Thus, this study aimed to clarify the difference in the clinical characteristics of GADA-ELISA-positive and GADA-ELISA-negative patients originally diagnosed as SPIDDM by GADA-RIA test. As a result, 42 of 63 original GADA-RIA-positive SPIDDM patients (66.7%) were found to be GADA-ELISA-positive, whereas the remaining 21 patients (33.3%) were found to be GADA-ELISA-negative. In patients with shorter disease duration, GADA-ELISA-positive patients showed significantly lower serum C-peptide levels than GADA-ELISA-negative patients. Meanwhile, in patients with longer disease duration, serum C-peptide levels were comparably decreased in GADA-ELISA-positive and GADA-ELISA-negative patients. A significant inverse correlation between serum C-peptide level and disease duration was observed in GADA-ELISA-negative patients, but not in GADA-ELISA-positive patients, suggesting that insulin secretory capacity may be gradually impaired over time also in GADA-ELISA-negative SPIDDM patients. In conclusion, physicians should be aware that GADA-ELISA-positive SPIDDM may be strongly associated with a future insulin-dependent state. Meanwhile, physicians should be careful in treating GADA-ELISA-negative SPIDDM patients diagnosed as type 2 DM, and cautiously follow the clinical course, in accordance with SPIDDM.Keywords
This publication has 14 references indexed in Scilit:
- Predictive value of titer of GAD antibodies for further progression of beta cell dysfunction in slowly progressive insulin-dependent (type 1) diabetes (SPIDDM)Diabetology International, 2015
- Diagnostic criteria for slowly progressive insulin-dependent (type 1) diabetes mellitus (SPIDDM) (2012): report by the Committee on Slowly Progressive Insulin-Dependent (Type 1) Diabetes Mellitus of the Japan Diabetes SocietyDiabetology International, 2015
- Type 1 Diabetes and AutoimmunityClinical Pediatric Endocrinology, 2014
- Autoantibodies to Insulin, Insulinoma-Associated Antigen-2, and Zinc Transporter 8 Improve the Prediction of Early Insulin Requirement in Adult-Onset Autoimmune DiabetesThe Journal of Clinical Endocrinology & Metabolism, 2010
- GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77Diabetologia, 2007
- Type 1 diabetes in JapanDiabetologia, 2006
- A sensitive non-isotopic assay for GAD65 autoantibodiesClinica Chimica Acta, 2003
- A proposal of three distinct subtypes of type 1 diabetes mellitus based on clinical and pathological evidenceAnnals of Medicine, 2000
- GAD Antibodies Seldom Disappear in Slowly Progressive IDDMDiabetes Care, 1996
- Type I Diabetes MellitusNew England Journal of Medicine, 1986